Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revision Previous revision
pd [2018/11/18 11:25]
sflitman [Parkinson's Disease]
pd [2019/07/21 11:48] (current)
sflitman [Parkinson's Disease]
Line 5: Line 5:
 ^ Condition(s) ^ Type of Drug ^ Phase ^ Add-On ^  Comparator ​ ^  Duration ​ ^  Open Label Extension ​ ^ ^ Condition(s) ^ Type of Drug ^ Phase ^ Add-On ^  Comparator ​ ^  Duration ​ ^  Open Label Extension ​ ^
 | Mild to Moderate Parkinson'​s Disease | Delayed Release Carbidopa/​Levodopa |  III  |  No   ​| ​ 50% get plain CD/LD  |  24 weeks  |  9 months ​ | | Mild to Moderate Parkinson'​s Disease | Delayed Release Carbidopa/​Levodopa |  III  |  No   ​| ​ 50% get plain CD/LD  |  24 weeks  |  9 months ​ |
 +| Moderate to Advanced Parkinson'​s Disease | Carbidopa/​Levodopa Continuous Subdermal infusion |  III  |  Yes  |  Sham infusion ​ | 12 months ​ |  Yes  |
 +| Dyskinesias in Parkinson'​s Disease | Novel oral agent |  II  |  Yes  |  33%  |  1 year  |  No  |
  
 <​html><​!-- <​html><​!--
-| Mild to Moderate Parkinson'​s Disease | Carbidopa/​Levodopa Accordion pill |  III  |  Yes  |  33%  |  12 weeks  |  No  | 
-| Moderate to Advanced Parkinson'​s Disease | Carbidopa/​Levodopa Continuous Subdermal infusion |  II  |  No  |  No  | 12 months ​ |  Yes  | 
 | Moderate to Severe Parkinson'​s Disease | Oral adenosine-2a antagonist |  III  |  Yes  |  33%  |  12 weeks  |  Yes  | | Moderate to Severe Parkinson'​s Disease | Oral adenosine-2a antagonist |  III  |  Yes  |  33%  |  12 weeks  |  Yes  |
 --></​html>​ --></​html>​
Print/export
QR Code
QR Code pd (generated for current page)